Gilead Sciences (NASDAQ:GILD) vs. Zura Bio (NASDAQ:ZURA) Head to Head Review

Gilead Sciences (NASDAQ:GILD) and Zura Bio (NASDAQ:ZURA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Earnings & Valuation

This table compares Gilead Sciences and Zura Bio’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$27.12 billion	3.21	$5.67 billion	$0.36	194.33
Zura Bio	N/A	N/A	-$69.24 million	N/A	N/A

Gilead Sciences has higher revenue and earnings than Zura Bio.

Profitability

This table compares Gilead Sciences and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	1.76%	24.34%	8.36%
Zura Bio	N/A	-64.56%	-50.33%

Analyst Recommendations

This is a breakdown of current recommendations for Gilead Sciences and Zura Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0	12	7	0	2.37
Zura Bio	0	0	5	1	3.17

Gilead Sciences presently has a consensus price target of $84.00, suggesting a potential upside of 20.07%. Zura Bio has a consensus price target of $19.75, suggesting a potential upside of 432.35%. Given Zura Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Gilead Sciences.

Volatility and Risk

Gilead Sciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Institutional & Insider Ownership

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 0.2% of Gilead Sciences shares are held by company insiders. Comparatively, 15.8% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Gilead Sciences beats Zura Bio on 8 of the 12 factors compared between the two stocks.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.